Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: Results in a single community-based hospital

Journal of Dermatology

Volumn 39, Issue 3, 2012, Pages 265-268

  Noda, Shinji ^a   Mizuno, Kyoko ^a   Adachi, Makoto ^a  

^a KANTO ROSAI HOSPITAL   (Japan)

Author keywords

adalimumab; infliximab; psoriasis; Psoriasis Area and Severity Index; Psoriasis Scalp Severity Index

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ADULT; AGED; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; INJECTION SITE REACTION; JAPANESE; MALE; PNEUMONIA; PSORIASIS; RESPIRATORY TRACT INFECTION; SCORING SYSTEM; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; SCALP DERMATOSES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84857647506     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01312.x     Document Type: Article

References (12)

1. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542. (Pubitemid 39278071)
2. Bonifati C, Carducci M, Cordiali Fei P, et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity. Clin Exp Dermatol 1994; 19: 383-387. (Pubitemid 24308596)
3. Mussi A, Bonifati C, Carducci M, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997; 11: 115-118. (Pubitemid 28045966)
4. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566. (Pubitemid 351239154)
5. van de Kerkhof PC, de Hoop D, de Korte J, et al. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998; 197: 326-334. (Pubitemid 29000784)
6. Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 60: 962-971.
7. de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996; 193: 300-303.
8. Thaçi D, Daiber W, Boehncke WH, et al. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology 2001; 203: 153-156. (Pubitemid 34701576)
9. Torii H, Nakagawa H, investigators JIS,. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 40-49.
10. Asahina A, Nakagawa H, Etoh T, et al. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010; 37: 299-310.
11. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115. (Pubitemid 350298146)
12. Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009; 219: 209-218.